a Sanofi company, announced today that the European Commission (EC) has
granted marketing authorization for Cerdelga® (INN:
eliglustat) capsules, a first line oral therapy for certain adults
living with Gaucher disease type 1. A small number of adult patients who
metabolize Cerdelga more quickly or at an undetermined rate, as detected
by an established genetic laboratory test, will not be eligible for
Cerdelga treatment. Cerdelga was approved by the U.S.more...